{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-02-10&min-answer.questionFirstAnswered.=2015-02-12T17%3A20%3A11.13Z&answer.answeringMemberConstituency=Battersea&hansardHeading=Hereditary+Diseases", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-date=2015-02-10&min-answer.questionFirstAnswered.=2015-02-12T17%3A20%3A11.13Z&answer.answeringMemberConstituency=Battersea&hansardHeading=Hereditary+Diseases", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-02-10&min-answer.questionFirstAnswered.=2015-02-12T17%3A20%3A11.13Z&answer.answeringMemberConstituency=Battersea&_metadata=all&hansardHeading=Hereditary+Diseases", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2015-02-10&min-answer.questionFirstAnswered.=2015-02-12T17%3A20%3A11.13Z&answer.answeringMemberConstituency=Battersea&hansardHeading=Hereditary+Diseases", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-02-10&min-answer.questionFirstAnswered.=2015-02-12T17%3A20%3A11.13Z&answer.answeringMemberConstituency=Battersea&hansardHeading=Hereditary+Diseases", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-02-10&min-answer.questionFirstAnswered.=2015-02-12T17%3A20%3A11.13Z&answer.answeringMemberConstituency=Battersea&hansardHeading=Hereditary+Diseases", "items" : [{"_about" : "http://data.parliament.uk/resources/179004", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/179004/answer", "answerText" : {"_value" : "

The Human Fertilisation and Embryology Authority has advised that if Parliament passes the Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it will need to design a regulatory process of which the consideration of \u201csignificant risk\u201d is a part. In designing that process it will take into account, where relevant, the existing regulatory process for embryo testing (preimplantation genetic diagnosis).<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2015-02-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-02-23T16:05:17.44Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-02-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Hereditary Diseases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, with reference to Part 5 (a) (ii) of the Mitochndrial Donation Regulations 2015, how the Human Fertilisation and Embryology Authority plans to define a \"significant risk\" of having or developing serious mitochondrial disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1569", "label" : {"_value" : "Biography information for Robert Flello"} } , "tablingMemberConstituency" : {"_value" : "Stoke-on-Trent South"} , "tablingMemberPrinted" : [{"_value" : "Robert Flello"} ], "uin" : "224080"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }